AnteoTech Ltd (AU:ADO)
ASX:ADO
Want to see AU:ADO full AI Analyst Report?
Top Page
AnteoTech Ltd
(Sydney:ADO)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.02
▼(-20.00% Downside)
Action:Reiterated
Date:05/22/26
Overall score is held down primarily by weak financial performance (losses, revenue volatility, and negative operating/free cash flow). Technicals are mixed—recent strength above moving averages and positive MACD, but an extremely overbought RSI increases downside risk. Valuation is also constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Proprietary surface-chemistry technology
AnteoTech’s proprietary surface-functionalisation technology is a durable competitive asset: it addresses core performance gaps in diagnostics and battery materials, enabling embedding into partners’ products. That IP-driven model supports recurring licensing, product sales and higher switching costs as partners qualify materials over long qualification cycles.
Negative Factors
Persistent negative margins
Ongoing negative operating, EBIT and EBITDA margins indicate structural profitability challenges: costs and scale economics have not been secured. Over the medium term this undermines self-funding capacity for commercialisation, increases reliance on external capital, and raises the risk of dilution or slowed growth if margins don’t improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary surface-chemistry technology
AnteoTech’s proprietary surface-functionalisation technology is a durable competitive asset: it addresses core performance gaps in diagnostics and battery materials, enabling embedding into partners’ products. That IP-driven model supports recurring licensing, product sales and higher switching costs as partners qualify materials over long qualification cycles.
Read all positive factors
AnteoTech Ltd (ADO) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$53.52M
Dividend YieldN/A
Average Volume (3M)1.47M
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth-45.25%
EPS Growth40.54%
CountryAU
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,973,138,700
10 Day Avg. Volume1,501,441
30 Day Avg. Volume1,471,917
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)10.79
Price to Sales (P/S)35.07
P/FCF Ratio-5.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$1.70M
AnteoTech Ltd Business Overview & Revenue Model
Company Description
AnteoTech Limited, a surface chemistry company, develops, commercializes, manufactures, and distributes products for the life sciences, diagnostics, energy, and medical device markets primarily in Australia. Its products include AnteoBind ready-to...
How the Company Makes Money
AnteoTech makes money primarily by commercialising its proprietary nanomaterial/surface-chemistry technologies into products and by partnering with third parties that embed its technology into their workflows and end-products. Key revenue streams ...
AnteoTech Ltd Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
40
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -995.80K | 968.88K | 460.40K | 365.72K | 760.88K | 898.07K |
| Gross Profit | -1.55M | 968.88K | 460.40K | 365.72K | 760.88K | 898.07K |
| EBITDA | -5.66M | -7.96M | -11.57M | -12.35M | -12.07M | -7.18M |
| Net Income | -3.69M | -6.76M | -8.88M | -12.65M | -10.72M | -6.22M |
Balance Sheet | ||||||
| Total Assets | 4.85M | 6.45M | 9.38M | 5.36M | 15.26M | 23.68M |
| Cash, Cash Equivalents and Short-Term Investments | 1.44M | 2.34M | 5.03M | 2.72M | 10.10M | 21.39M |
| Total Debt | 2.85M | 1.96M | 2.31M | 1.31M | 1.03M | 1.28M |
| Total Liabilities | 2.82M | 3.30M | 4.08M | 2.99M | 2.91M | 2.56M |
| Stockholders Equity | 2.03M | 3.15M | 5.31M | 2.38M | 12.36M | 21.11M |
Cash Flow | ||||||
| Free Cash Flow | -2.90M | -6.05M | -7.58M | -8.77M | -11.77M | -4.76M |
| Operating Cash Flow | -2.82M | -5.83M | -6.52M | -8.08M | -8.65M | -4.55M |
| Investing Cash Flow | -118.14K | -174.87K | -1.06M | -690.83K | -3.12M | -213.07K |
| Financing Cash Flow | -704.07K | 3.32M | 9.89M | 1.39M | 482.29K | 22.94M |
AnteoTech Ltd Technical Analysis
Positive
0.02
Price Trends
0.01
Positive
0.01
Positive
0.02
Positive
Market Momentum
<0.01
Negative
99.62
Negative
35.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ADO, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 99.62 is Negative, neither overbought nor oversold. The STOCH value of 35.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ADO.
AnteoTech Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$86.22M | -5.28 | -62.49% | ― | ― | -13.64% | |
49 Neutral | AU$49.80M | -6.66 | -370.40% | ― | 9.28% | -40.00% | |
47 Neutral | AU$260.98M | 27.58 | -15.96% | ― | 364.97% | 74.50% | |
45 Neutral | AU$68.17M | -7.57 | -179.37% | ― | ― | 24.59% | |
43 Neutral | AU$53.52M | -10.60 | -142.30% | ― | -45.25% | 40.54% | |
42 Neutral | AU$23.95M | -4.45 | -93.66% | ― | -23.71% | -16.02% |
* Healthcare Sector Average
AU:ADO
AnteoTech Ltd
0.02
<0.01
80.00%
AU:CYP
Cynata Therapeutics Limited
0.28
0.10
55.56%
AU:PTX
Prescient Therapeutics Limited
0.08
0.04
78.26%
AU:SPL
Starpharma Holdings Limited
0.62
0.53
588.89%
AU:AVE
Avecho Biotechnology Limited
0.01
<0.01
30.00%
AU:PIQ
Proteomics International Laboratories Ltd.
0.15
-0.26
-63.75%
AnteoTech Ltd Corporate Events
AnteoTech’s Ultranode 95 Anode Wins Key U.S. Validation for Drone-Ready Batteries
May 21, 2026
AnteoTech has secured independent third-party validation of its Ultranode™ 95 high-silicon anode in 5 Ah multi-layer pouch cells at the U.S.-based Battery Innovation Centre, confirming commercial scalability and strong manufacturability. The...
AnteoTech options lapse, trimming future dilution risk
May 11, 2026
AnteoTech Ltd has confirmed the expiry of two tranches of listed options without exercise, resulting in the cessation of 10,075,000 options from its capital structure. The expired options, with exercise prices of $0.048 and original expiry dates i...
AnteoTech Warns Holders on Imminent Expiry of 286.6m Listed Options
May 5, 2026
AnteoTech Ltd has notified holders of its ASX-listed options (ticker ADOO) that these securities, exercisable at $0.035, will expire on 31 May 2026, and their official quotation will cease on 25 May 2026. Option holders must submit a valid exercis...
AnteoTech advances battery and diagnostics commercialisation with new validations and CLIA partnership
Apr 20, 2026
AnteoTech reported a March 2026 quarter centred on commercial execution, with record product sample dispatches, expanded participation in global industry forums and steady progress in converting its enlarged sales pipeline. In Advanced Battery Tec...
AnteoTech outlines immunodiagnostics strategy at virtual healthcare conference
Mar 25, 2026
AnteoTech used the NWR Virtual Healthcare Conference on 26 March 2026 to provide an update on its immunodiagnostics business centered on its AnteoBind surface chemistry technology. The company positioned the presentation as a high-level business u...
AnteoTech flags high-silicon anode focus at Florida battery seminar
Mar 24, 2026
AnteoTech has used a presentation at the 43rd Florida International Battery Seminar to update stakeholders on its work to maximise high silicon anode performance, a key focus area for improving lithium-ion battery energy density. The company posit...
AnteoTech to Showcase Healthcare Strategy at NWR Virtual Conference
Mar 23, 2026
AnteoTech Ltd, an ASX-listed supplier of advanced materials to the battery and life sciences diagnostics sectors, builds on a proprietary cross-linking chemistry platform to deliver products that enhance battery performance and point-of-care test ...
AnteoTech Moves to Enter US$13bn CLIA Market With New Immunoassay Partnership
Mar 2, 2026
AnteoTech has entered an agreement with a large global life sciences company to launch an initial work program developing activated magnetic particles using its AnteoBind NXT technology for chemiluminescent immunoassays. The initiative aims to cre...
AnteoTech Issues Cautious Investor Briefing for First Half FY 2026
Mar 1, 2026
AnteoTech has released an investor briefing for the first half of FY 2026, outlining an update on its business operations, financial condition and market environment. The document emphasises that the material is an informational aid only, relies i...
AnteoTech Narrows Half-Year Loss Despite Sharp Revenue Fall on Contract Timing
Feb 25, 2026
AnteoTech Ltd has released its interim financial report for the half year ended 31 December 2025, detailing a sharp fall in reported revenue from ordinary activities alongside a narrower loss. Revenue from ordinary activities declined 85% to $97,0...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.